Publications financières Archive - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
Publications financières Archive - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
  • Our Company
    • Presentation
    • Management Team
    • Board of directors
    • Scientific Advisory Board
    • Contact
  • Products
    • Tedopi®
    • OSE-279
    • Lusvertikimab (OSE-127)
    • Pegrizeprument (FR104)
    • BI 770371
    • ABBV-230
    • CLEC-1
  • Research & Development
    • Scientific publications
  • Investors
    • Press Releases
    • Regulated information
    • Financial documents
    • General Shareholders’ meetings
  • Partnerships
    • Pharma partnerships
    • Clinical partnerships
    • Academic and public Partnerships
  • News
    • Agenda
    • Press Releases
  • Contact
en
  • fr

Projects Archives

September 2024

First-half 2024 semester report (in French)

July 2024

2023 Universal registration document

September 2023

Auditors’s report on first-half 2023 financial report (in French)

September 2023

First-half 2023 financial report (in French)

May 2023

2022 Universal registration document

September 2022

Statutory Auditors’ report on the condensated half-year financial statements (in French)

September 2022

First-half 2022 financial report

April 2022

2021 Universal registration document

October 2021

First-half 2021 financial report

October 2021

2020 Universal registration document

  • 1
  • 2
  • Suivant

Head Office

22, boulevard Benoni Goulin
44200 Nantes – France

Tel : +33 (0)2 28 29 10 10

Email : contact@ose-immuno.com

Paris Office

10, place de Catalogne
75014 Paris – France

Tel : +33 (0)1 43 29 78 57

Fax : +33 (0)1 42 03 04 16

Our Company
Products
Investors
Agenda
Research & Development
Partnerships
Press Releases
Follow us
©2021 ose-immuno
Financial documents
Legal information and Personal data protection policy
Site internet créé par Adveris